Medicine that help in leprosy nerve problem

Effect of oral alpha lipoic acid supplementation on nerve function impairment assessed using nerve conduction studies and ultrasound techniques among newly diagnosed leprosy patients: A Pilot randomized clinical trial. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/059232

Enrollment

Registered

2023-10-27

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A30- Leprosy [Hansens disease]

Interventions

Intervention1: Alpha Lipoic Acid: Tablet Alpha Lipoic Acid 600 mg once a day for three months Control Intervention1: Standard Treatment of leprosy: Standard Treatment of leprosy

Eligibility

Inclusion criteria

Inclusion criteria: 1. Those willing to participate. 2. Age group between 18-60 yrs. 3. Newly diagnosed leprosy patients with abnormal Nerve conduction study

Exclusion criteria

Exclusion criteria: 1. Subject with significant spinal, renal, hepatic impairment, diabetes and fixed deformities. 2. Subject with known hypersensitivity with antioxidants. 3. Pregnancy and Lactating mothers. 4. Diagnosed case of neuropathy related to other causes 5. Leprosy patients on thalidomide and/or minocycline treatment. 6. Newly diagnosed leprosy patients receiving any other antioxidants

Design outcomes

Primary

Measure	Time frame
Proportion of patients showing improvements in treatment group compare to control group in initial three months.Timepoint: 03 Months	—

Secondary

Measure	Time frame
Proportion of patients showing Adverse drug reaction in treatment group compare to control group in initial three months.Timepoint: 03 months	—

Countries

India

Contacts

Public ContactDoctor Avinash S Ingle

All India institute of Medical Sciences Raipur

dravinashingle@aiimsraipur.edu.in799975490

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026